Expert Interview
Discussing commercial use of Rezdiffra and the topline results of the ESSENCE trial
Ticker(s): MDGLInstitution: Massachusetts General Hospital
- Director of Hepatology and Liver Center & Vice Chief of Gastroenterology at Massachusetts General Hospital.
- Treats 75 patients with PSC and 400 patients with NASH.
- Research interest in liver disease pathogenesis in persons with HIV, viral hepatitis, and defining biomarkers and gene signatures for persons at high risk for liver disease progression and liver cancer.
Can you provide an overview of your practice and your professional background in hepatology and liver disease management?
How many NASH patients do you manage, and how many of them are receiving Rezdiffra? What methods do you use to confirm their F2-F3 status?
Added By: slingshot_insightsWhat are your observations on the efficacy and safety of Rezdiffra, and how do patient feedback and adverse events impact treatment continuation?
Added By: slingshot_insightsHow do the latest ESSENCE trial data and other emerging therapies like GLP-1s and FGF-21s influence your approach to managing NASH patients, especially with metabolic predispositions?
Added By: slingshot_insightsWhat is your perspective on the future evolution of the NASH treatment market over the next three to five years, particularly in terms of drug classes and market share dynamics?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
